摘要
早先发现,对应于晚期糖基化终产物受体(RAGE)细胞外结构域60-76序列的合成片段对阿尔茨海默病的动物和细胞模型具有保护作用。有人提出,这种作用是通过肽与作为 RAGE 配体之一的 β-淀粉样蛋白 (Aβ) 的相互作用通过抑制有毒 Aβ 寡聚体的形成来介导的。本研究的目的是应用物理化学方法研究 60-76 肽与非保护性 65-76 截短肽相比防止溶液中 Aβ40 寡聚化的能力。使用硫代黄素 T 评估在肽存在下 Aβ40 原纤维形成的动力学。低聚物的相对尺寸通过动态光散射确定。通过荧光滴定检查与 Aβ40 结合的肽。我们通过两种方法证明,对应于 RAGE 的 60-76 序列的肽显着抑制(超过 90%)与 65-76 肽不同的 Aβ40 低聚物和原纤维的形成。此外,我们发现肽的保护作用及其抑制 Aβ40 寡聚化的能力与它们与单体/四聚体 Aβ40 的结合无关。我们在体外证实了这一假设,即 RAGE 的合成 60-76 片段的保护活性与其抑制 Aβ 寡聚化的能力有关。我们通过两种方法证明,对应于 RAGE 的 60-76 序列的肽显着抑制(超过 90%)与 65-76 肽不同的 Aβ40 低聚物和原纤维的形成。此外,我们发现肽的保护作用及其抑制 Aβ40 寡聚化的能力与它们与单体/四聚体 Aβ40 的结合无关。我们在体外证实了这一假设,即 RAGE 的合成 60-76 片段的保护活性与其抑制 Aβ 寡聚化的能力有关。我们通过两种方法证明,对应于 RAGE 的 60-76 序列的肽显着抑制(超过 90%)与 65-76 肽不同的 Aβ40 低聚物和原纤维的形成。此外,我们发现肽的保护作用及其抑制 Aβ40 寡聚化的能力与它们与单体/四聚体 Aβ40 的结合无关。我们在体外证实了这一假设,即 RAGE 的合成 60-76 片段的保护活性与其抑制 Aβ 寡聚化的能力有关。我们发现肽的保护作用及其抑制 Aβ40 寡聚化的能力与它们与单体/四聚体 Aβ40 的结合无关。我们在体外证实了这一假设,即 RAGE 的合成 60-76 片段的保护活性与其抑制 Aβ 寡聚化的能力有关。我们发现肽的保护作用及其抑制 Aβ40 寡聚化的能力与它们与单体/四聚体 Aβ40 的结合无关。我们在体外证实了这一假设,即 RAGE 的合成 60-76 片段的保护活性与其抑制 Aβ 寡聚化的能力有关。
"点击查看英文标题和摘要"
Biologically Active Fragment of the Receptor for Advanced Glycation End Products (RAGE) Is Able to Inhibit Oligomerization of the Beta-Amyloid
Abstract
It was found earlier that the synthetic fragment corresponding to the 60–76 sequence of the extracellular domain of the receptor for advanced glycation end products (RAGE) had a protective effect on animal and cellular models of Alzheimer’s disease. It was proposed that this effect was mediated via the interaction of the peptide with beta-amyloid (Aβ), which was one of the RAGE ligands, by inhibiting the formation of toxic Aβ oligomers. The aim of this study was an application of physicochemical methods to an investigation of the ability of the 60–76 peptide to prevent the Aβ40 oligomerization in solution in comparison with the nonprotective 65–76 truncated peptide. The dynamics of the formation of the Aβ40 fibrils in the presence of the peptides was evaluated using thioflavin T. The relative sizes of oligomers were determined by dynamic light scattering. The peptide binding to Aβ40 was examined by fluorescence titration. We demonstrated by the two methods that the peptide corresponding to the 60–76 sequence of RAGE considerably inhibited (by more than 90%) the formation of oligomers and fibrils of Aβ40 distinct from the 65–76 peptide. In addition, we found that the protective effect of the peptides and their ability to inhibit the Aβ40 oligomerization did not correlate with their binding to the monomeric/tetrameric Aβ40. We confirmed in vitro the hypothesis that the protective activity of the synthetic 60–76 fragment of RAGE was associated with its ability to inhibit the Aβ oligomerization.